Resources

Sanofi UK, a leading pharmaceutical company, sought an innovative solution to address challenges in clinical trial recruitment and feasibility.

There has been a proliferation of large-scale electronic health record (EHR) data platforms that pool across multiple healthcare organizations

Discover how partnering with TriNetX will enable you to advance rare disease research.

In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.

Pediatric obstructive sleep apnea (OSA) affects an estimated 1–3 % of children, corresponding to over 40 million cases globally.

Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.

TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2022 standard and maintains an Information Security Management System

Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting

Dr. David Karp, Chief of the Division of Rheumatic Diseases at UT Southwestern Medical Center, leads research efforts in systemic lupus erythematosus (SLE), a rare and complex autoimmune condition that disproportionately affects women of color.

Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum.

Clinical trials often falter at the final stretch—when it’s time to execute. It’s here that well-intentioned protocols meet real-world complexity, where timelines can slip, costs may surge, and outcomes could fall short of expectations.

This TriNetX exclusive survey report reveals how 150 senior pharmaceutical and biotech executives are leveraging artificial intelligence, real-world data (RWD), and diversity in clinical trials to drive innovation—while navigating persistent challenges.